Status:
COMPLETED
Allergic Rhinitis With/Without Asthma: Pre- and Post-Qipian Analysis
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Rhinitis, Allergic
Asthma
Eligibility:
All Genders
18-50 years
Brief Summary
Allergic rhinitis and asthma are common respiratory diseases. Qipian® is a Chinese medicine made from three types of bacteria, used to treat these conditions. This study will retrospectively analyze t...
Detailed Description
Allergic rhinitis and asthma are common chronic respiratory diseases, with rising prevalence each year. Bacterial lysates (BLs) are a potential treatment option that has been used for over 100 years. ...
Eligibility Criteria
Inclusion
- Patients with rhinitis who meet the ARIA (Allergic Rhinitis and Its Impact on Asthma) guidelines.
- Patients with asthma who meet the GINA (Global Initiative for Asthma) guidelines.
Exclusion
- Patients undergoing combined dust mite-specific immunotherapy
- Patients undergoing combined treatment with biologics, including omalizumab, dupilumab, or mepolizumab.
- Patients undergoing combined treatment with small molecule drugs, including upadacitinib, abrocitinib, baricitinib, and other JAK inhibitors.
- Patients who are unwilling to comply with treatment, are unable to adhere to regular medication schedules, and do not attend follow-up appointments.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06573164
Start Date
January 1 2024
End Date
July 31 2024
Last Update
August 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310009